Roots Analysis
APRIL 20, 2022
This continuously growing pipeline of pharmaceutical drug products has inadvertently led to an increase in the demand for their associated primary packaging and Secondary Packaging solutions. . 3] Some of the advantages offered by pharmaceutical secondary packaging have been depicted below. Company Competitiveness Analysis.
pharmaphorum
JANUARY 28, 2021
For PRISYM ID client RxSource , a Global Clinical Trial Supplies Specialist, it means being ready to partner with sponsor companies to get everything set up for a clinical trial within a week, including packaging and labeling. This was an incredibly fast turnaround for what could easily have been a long and arduous onboarding process.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The FDA Law Blog
AUGUST 17, 2023
Vanda requested that FDA revoke the approval of Apotex’s and Teva’s generic versions of Hetlioz on the grounds that the generic tasimelteon products did not meet the statutory “same labeling” requirement for generic drugs found in 21 U.S.C. § Vanda’s Hetlioz was, in fact, the first FDA-approved drug product to include braille labeling.
Pharma Marketing Network
AUGUST 9, 2023
Maintain a balanced approach by presenting both the benefits and potential risks of the medication or treatment. Adhere to Labeling and Packaging Requirements The labeling and packaging of pharmaceutical products are tightly regulated to ensure safety and accurate information.
Pharma Marketing Network
AUGUST 9, 2023
Maintain a balanced approach by presenting both the benefits and potential risks of the medication or treatment. Adhere to Labeling and Packaging Requirements The labeling and packaging of pharmaceutical products are tightly regulated to ensure safety and accurate information.
The FDA Law Blog
FEBRUARY 16, 2023
While laypeople are already using NNS in a number of states, FDA has cautioned that the current community use differs from OTC use because many of these programs provide patient counseling and instructions for use that go beyond what is included in the current NNS labeling.
European Pharmaceutical Review
MARCH 14, 2023
This concerns the quantity of the medicinal product in the packaging, ie, the increase or decrease in the number of units of the product in the outer packaging according to local demands and its labelling, including the leaflet, which should be in the language of the country into which the product is imported.
Expert insights. Personalized for you.
52 
Let's personalize your content